Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at ...

U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- ...

Among children treated with an oral agent, the recurrence rate was 16/42 (38.1%) following penicillin or amoxicillin and 10/36 (27.8%) following a beta-lactamase resistant agent (adjusted odds ...

Xediton Pharmaceuticals Inc. is proud to announce that Vabomere® (meropenem-vaborbactam) has been approved by Health Canada and is now commercially ...

Among the 26 patients who had at least 1 recurrence, early symptoms developed in 11 (68.8%) of 16 treated with amoxicillin or penicillin and in 5 (50.0%) of 10 treated with a beta-lactamase ...

In addition, antibiotic resistance is spread by the misuse of antibiotics ... caused by multiresistant klebsiella pneumoniae producing new delhi metallo-beta-lactamase (NDM-1) with strains genotyping.

The OxStu discusses the causes and implications of antimicrobial resistance, and the social and scientific methods to combat it.

Evidence of the impact of extended-spectrum beta-lactamase production on mortality and length ... Because estimates of clinical burden drive policy design for antibiotic stewardship and infection ...

O isolamento de bactérias produtoras de beta-lactamases de espectro expandido (ESBL ... and the transconjugant isolates were resistant to extended spectrum β-lactam antibiotics, these β-lactamases ...